IKZF1 status as a prognostic feature in BCR-ABL1-positive childhood ALL

Blood

Volumn 123, Issue 11, 2014, Pages 1691-1698

  Van Der Veer, Arian ^a   Zaliova, Marketa ^b,c   Mottadelli, Federica ^d   De Lorenzo, Paola ^d   Te Kronnie, Gertruuy ^e   Harrison, Christine J ^f   Cavé, Hélène ^g   Trka, Jan ^c   Saha, Vaskar ^h   Schrappe, Martin ^b   Pieters, Rob ^a,i   Biondi, Andrea ^d   Valsecchi, Maria Grazia ^d   Stanulla, Martin ^b,j   Den Boer, Monique L ^a,i   Cazzaniga, Giovanni ^d  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^d UNIVERSITY OF MILANO BICOCCA   (Italy)

^e UNIVERSITY OF PADOVA   (Italy)

^f NEWCASTLE UNIVERSITY   (United Kingdom)

^g HÔPITAL ROBERT DEBRÉ   (France)

^h UNIVERSITY OF MANCHESTER   (United Kingdom)

ⁱ DCOG Dutch Childhood Oncology Group   (Netherlands)

^j HANNOVER MEDICAL SCHOOL   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; IKAROS FAMILY ZINC FINGER 1; IKAROS TRANSCRIPTION FACTOR; IMATINIB; PREDNISONE; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANCER PROGNOSIS; CANCER RISK; CHILD; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GENE DELETION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRE B LYMPHOCYTE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD;

ANTINEOPLASTIC AGENTS; BENZAMIDES; CHILD; CHROMOSOME ABERRATIONS; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; FUSION PROTEINS, BCR-ABL; HUMANS; IKAROS TRANSCRIPTION FACTOR; MALE; PHILADELPHIA CHROMOSOME; PIPERAZINES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; PYRIMIDINES; SEQUENCE DELETION; SURVIVAL RATE;

EID: 84897566266     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-06-509794     Document Type: Article

References (33)

1. Pui CH, Carroll WL, Meshinchi S, Arceci RJ. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol. 2011;29(5):551-565.
2. Pui C-H, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006;354(2):166-178. (Pubitemid 43076714)
3. Aricò M, Schrappe M, Hunger SP, et al. Clinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005. J Clin Oncol. 2010;28(31):4755-4761.
4. Takeuchi J, Kyo T, Naito K, et al. Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: the JALSG-ALL93 study. Leukemia. 2002;16(7):1259-1266.
5. Moorman AV, Ensor HM, Richards SM, et al. Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97/99 randomised trial. Lancet Oncol. 2010;11(5):429-438.
6. Aricò M, Valsecchi MG, Camitta B, et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med. 2000;342(14):998-1006. (Pubitemid 30180646)
7. Mizuta S, Matsuo K, Yagasaki F, et al. Pre-transplant imatinib-based therapy improves the outcome of allogeneic hematopoietic stem cell transplantation for BCR-ABL-positive acute lymphoblastic leukemia. Leukemia. 2011;25(1):41-47.
8. Schultz KR, Bowman WP, Aledo A, et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study. J Clin Oncol. 2009;27(31):5175-5181.
9. Biondi A, Schrappe M, De Lorenzo P, et al. Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study. Lancet Oncol. 2012;13(9):936-945.
10. Slayton WB, Schultz KR, Jones T, et al. Outstanding early responses with dasatinib and intensive chemotherapy in pediatric philedelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL): Children's Oncology Group (COG) trial AALL0622. Pediatr Blood Cancer. 2012;59(6):988.
11. Cazzaniga G, van Delft FW, Lo Nigro L, et al. Developmental origins and impact of BCR-ABL1 fusion and IKZF1 deletions in monozygotic twins with Ph+ acute lymphoblastic leukemia. Blood. 2011;118(20):5559-5564.
12. Conter V, Bartram CR, Valsecchi MG, et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood. 2010;115(16):3206-3214.
13. Iacobucci I, Iraci N, Messina M, et al. IKAROS deletions dictate a unique gene expression signature in patients with adult B-cell acute lymphoblastic leukemia. PLoS ONE. 2012;7(7):e40934.
14. Kuiper RP, Waanders E, van der Velden VHJ, et al. IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL. Leukemia. 2010;24(7):1258-1264.
15. Mullighan CG, Su X, Zhang J, et al Children's Oncology Group. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med. 2009;360(5):470-480.
16. Waanders E, van der Velden VH, van der Schoot CE, et al. Integrated use of minimal residual disease classification and IKZF1 alteration status accurately predicts 79% of relapses in pediatric acute lymphoblastic leukemia. Leukemia. 2011;25(2):254-258.
17. Yang YL, Hung CC, Chen JS, et al. IKZF1 deletions predict a poor prognosis in children with B-cell progenitor acute lymphoblastic leukemia: a multicenter analysis in Taiwan. Cancer Sci. 2011;102(10):1874-1881.
18. Dörge P, Meissner B, Zimmermann M, et al. IKZF1 deletion is an independent predictor of outcome in pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol. Haematologica. 2013;98(3):428-432.
19. van der Veer A, Waanders E, Pieters R, et al. Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL. Blood. 2013;122(15):2622- 2629.
20. Merkenschlager M. Ikaros in immune receptor signaling, lymphocyte differentiation, and function. FEBS Lett. 2010;584(24):4910-4914.
21. Trageser D, Iacobucci I, Nahar R, et al. Pre-B cell receptor-mediated cell cycle arrest in Philadelphia chromosome-positive acute lymphoblastic leukemia requires IKAROS function. J Exp Med. 2009;206(8):1739-1753.
22. Iacobucci I, Lonetti A, Cilloni D, et al. Identification of different Ikaros cDNA transcripts in Philadelphia-positive adult acute lymphoblastic leukemia by a high-throughput capillary electrophoresis sizing method. Haematologica. 2008;93(12):1814-1821.
23. Martinelli G, Iacobucci I, Storlazzi CT, et al. IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report. J Clin Oncol. 2009;27(31):5202-5207.
24. Den Boer ML, van Slegtenhorst M, De Menezes RX, et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol. 2009;10(2):125-134.
25. Iacobucci I, Storlazzi CT, Cilloni D, et al. Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute Leukemia Working Party (GIMEMA AL WP). Blood. 2009;114(10):2159-2167.
26. Mullighan CG, Miller CB, Radtke I, et al. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature. 2008;453(7191):110-114. (Pubitemid 351630327)
27. Bungaro S, Dell'Orto MC, Zangrando A, et al. Integration of genomic and gene expression data of childhood ALL without known aberrations identifies subgroups with specific genetic hallmarks. Genes Chromosomes Cancer. 2009;48(1):22-38.
28. Fine J, Gray R. A proportional hazards model for the subdistribution of competing risk. J Am Stat Assoc. 1999;94:496-509.
29. Caye A, Beldjord K, Mass-Malo K, et al. Breakpoint-specific multiplex polymerase chain reaction allows the detection of IKZF1 intragenic deletions and minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia. Haematologica. 2013;98(4):597-601.
30. Suzuki K, Ono R, Ohishi K, et al. IKAROS isoform 6 enhances BCR-ABL1-mediated proliferation of human CD34+ hematopoietic cells on stromal cells. Int J Oncol. 2012;40(1):53-62.
31. Feldhahn N, Klein F, Mooster JL, et al. Mimicry of a constitutively active pre-B cell receptor in acute lymphoblastic leukemia cells. J Exp Med. 2005;201(11):1837-1852. (Pubitemid 41002902)
32. Nacheva EP, Brazma D, Virgili A, et al. Deletions of immunoglobulin heavy chain and T cell receptor gene regions are uniquely associated with lymphoid blast transformation of chronic myeloid leukemia. BMC Genomics. 2010;11:41.
33. Heerema NA, Harbott J, Galimberti S, et al Acute Lymphoblastic Leukemia Study Groups; ALL-BFM; CoALL; AIEOP; DCLSG; FRALLE; CCG; DFCI; POG; St Jude; UKALL. Secondary cytogenetic aberrations in childhood Philadelphia chromosome positive acute lymphoblastic leukemia are nonrandom and may be associated with outcome. Leukemia. 2004;18(4):693-702. (Pubitemid 38500187)